pemetrexed / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

180 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pemetrexed / Generic mfg.
CTR20201857: Phase III clinical study of ametinib mesylate or placebo combined with chemotherapy as perioperative treatment for non-small cell lung cancer

Not yet recruiting
3
350
China
Ameile (aumolertinib) - Jiangsu Hansoh Pharma, EQRx, Pemfexy (pemetrexed) - Eagle Pharma, cisplatin - Generic mfg., carboplatin - Generic mfg.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd./Shanghai Hansoh Biomedical Technology Co., Ltd.
Non-small cell lung cancer;Oncology
 
 
WJOG11218L, jRCT2080224500: A multicentre, open-label, randomized Phase III Study of Atezolizumab with Platinum-Pemetrexed with or without Bevacizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer ( Investigator-Initiated Clinical Trial)

Completed
3
400
Japan
Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche, carboplatin - Generic mfg., pemetrexed - Generic mfg.
Kyushu University Hospital, Chugai Pharmaceutical Co., Ltd
Non-Small-Cell Lung Cancer;Oncology
 
 
ACHILLES , jRCTs031180175: study/TORG1834 (study/TORG1834)

Active, not recruiting
3
106
Japan
Gilotrif (afatinib) - Boehringer Ingelheim, cisplatin - Generic mfg., carboplatin - Generic mfg., pemetrexed - Generic mfg.
Niigata Cancer Center Hospital
Advanced non-small cell lung cancer
 
 
ZEAL, NCT00418886 / 2006-003695-35: Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

Checkmark Data
Feb 2011 - Feb 2011: Data
Completed
3
698
Europe, US, RoW
Vandetanib, ZACTIMA™, ZD6474, SAR390530, Pemetrexed, Pemetrexed disodium, Alimta®
Genzyme, a Sanofi Company
Non Small Cell Lung Cancer, Lung Cancer
09/08
02/23
NCT00049426: Gemcitabine With or Without Pemetrexed Disodium in Treating Patients With Unresectable Stage II, Stage III, or Stage IV Pancreatic Cancer

Active, not recruiting
3
US
cyanocobalamin, folic acid, gemcitabine hydrochloride, pemetrexed disodium
Ireland Cancer Center, National Cancer Institute (NCI)
Pancreatic Cancer
 
 
ChiCTR-TRC-09000487: A randomized multicentre control trial of stage III non-small cell lung cancer application of concomitant radiochemotherapy

Completed
3
240
 
to receive concomitant radiochemotherapy with pemetrexed + cisplatin: pemetrexed 500mg/m2, i.v. drip d1; cisplatin 25mg/m2, i.v. drip d1-3. Radiotherapy carried out in the 1st and 4th week. ;to receive concomitant radiochemotherapy with vinorelbine and cisplatin: Vinorelbine 25mg/m2, i.v. drip d1, 8; cisplatin 25mg/m2, i.v. drip d1-3. Radiotherapy carried out in the 1st and 4th week.
Shandong Cancer Hospital; Jiangsu Hansen Pharmaceutical Co. Ltd, Shandong Provincial Scientific and Technological Project
Non-small cell lung cancer
 
 
ChiCTR-TRC-10000774: A multicenter randomized phase III trial to compare weekly usage with triweekly usage of docetaxel and cisplatin in concurrent chemoradio-therapy for patients with locally advaced non-small cell lun

Completed
3
200
 
The concurrent chemotherapy consisted of Docetaxel 60 mg/m2, on day 1 and Cisplatin 30mg/m2 , on day 1 and day 2, repeated every three weeks for a total of six weeks. Consolidation chemotherapy were performed after 4 to 6 weeks following the completion of concurrent chemoradiotherapy. Which consisted of of Docetaxel 35 mg/m2, on day 1 and Cisplatin 35mg/m2 , on day 1 and day 8, repeated every three weeks for a total of six weeks. TKI or pemetrexed were recommended to patients with progression of ;The concurrent chemotherapy consisted of Docetaxel and Cisplatin 20mg/m2 , on day 1, repeated every week for a total of six weeks. The same consolidation chemotherapy regime as A.
Beijing Cancer Hospital; Level of the institution：, No
Locally advanced non-small cell lung cancer
 
 
2013-004303-39: Study with erlotinib compared to intercalated erlotinib with cisplatinum pemetrexed for advanced lung cancer

Ongoing
3
150
Europe
Tarceva, Cisplatine, Alimta, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Tarceva, Cisplatine, Alimta
Stichting NVALT Studies, Stichting NVALT Studies
Advanced non-small cell lung cancer, lung cancer, Diseases [C] - Cancer [C04]
 
 
NCT00324805: Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark From ECOG 1505 trial for lung cancer (adjuvant)
Feb 2016 - Feb 2016: From ECOG 1505 trial for lung cancer (adjuvant)
Checkmark Data-WCLC
More
Active, not recruiting
3
1501
Europe, Canada, US, RoW
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Questionnaire Administration, Vinorelbine Tartrate, Biovelbin, Eunades, KW-2307, Navelbine, Navelbine Ditartrate, NVB, Vinorelbine Ditartrate
National Cancer Institute (NCI), Cancer and Leukemia Group B, NCIC Clinical Trials Group, North Central Cancer Treatment Group, SWOG Cancer Research Network
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
10/15
10/24
2007-002608-16: A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in patients with high risk for recurrence and completely resected non-small-cell lung cancer: NVALT-8B

Ongoing
3
600
Europe
Alimta, Fraxodi, Alimta, Fraxodi, Alimta
UMCG
This is a randomized multicenter phase III study. Patient with a high SUVof the primary tumor prior to surgery will be randomised to four cycles of pemetrexed and cisplatin with or without nadroparin for 16 weeks in order to improve the recurrence-free survival rate in these patients.
 
 
2007-002644-21: A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low-risk for recurrence: NVALT-8A

Ongoing
3
864
Europe
cisplatine, Vinorelbine, Gemzar, Alimta, Cisplatine, Vinorelbine, Gemzar, Alimta, Cisplatine, Vinorelbine, Gemzar, Alimta
UMCG
This is a randomized multicenter phase III study. Patient with a low SUV of the primary tumor prior to surgery will be randomised to four cycles of cisplatin-based chemotherapy or observation in a non-inferiority design.
 
 
NCT01828112 / 2012-005637-36: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Completed
3
231
Europe, Canada, Japan, US, RoW
Ceritinib, pemetrexed, docetaxel
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
01/16
11/23
2016-001063-36: Randomised phase III study testing nivolumab versus chemotherapy in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer Etude randomisée de phase III testant le nivolumab versus une chimiothérapie adaptée dans le traitement de première ligne du CBNPC chez des patients PS 2 ou de plus de 70 ans

Ongoing
3
242
Europe
nivolumab, carboplatin, pemetrexed, paclitaxel, gemcitabine, vinorelbine, Solution for infusion, Solution for injection, Powder for concentrate for solution for infusion, Powder for solution for infusion, Capsule, soft, OPDIVO
CHU Rennes, Bristol-Myers Squibb
Advanced non small cell lung cancer Cancer Bronchique Non à Petites Cellules avancé, Advanced non small cell lung cancer Cancer Bronchique Non à Petites Cellules avancé, Diseases [C] - Cancer [C04]
 
 
ASCEND-4, NCT01828099 / 2013-000319-26: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Checkmark ASCEND-4 trial in ALK+ NSCLC
Apr 2017 - Apr 2017: ASCEND-4 trial in ALK+ NSCLC
Checkmark ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Sep 2016 - Sep 2016: ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Completed
3
376
Europe, Japan, RoW
Ceritinib, LDK378, Pemetrexed, Cisplatin, Carboplatin
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
06/16
01/24
KEYNOTE-189, NCT02578680 / 2015-003694-15: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/)

Checkmark From KEYNOTE-189 trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC at ESMO – IO 2019
Dec 2019 - Dec 2019: From KEYNOTE-189 trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC at ESMO – IO 2019
Checkmark Data from KEYNOTE-189 trial for NSCLC at IASLC-WCLC 2019
Sep 2019 - Sep 2019: Data from KEYNOTE-189 trial for NSCLC at IASLC-WCLC 2019
Checkmark Updated data in combination with Alimta for metastatic nonsquamous 1L NSCLC
More
Completed
3
616
NA
Pembrolizumab 200 mg, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg, Saline solution
Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
11/17
06/23
2012-000092-16: Study evaluating two maintenance strategies (continuous and according to the response of chemotherapy in advanced lung cancer) Etude évaluant deux stratégies de maintenance (maintenance de continuation et maintenance en fonction de la réponse à la chimiothérapie) dans le cancer du poumon de stade avancé

Not yet recruiting
3
918
Europe
NA, NA, Solution for infusion, Powder for solution for infusion, Alimta, Cisplatin, Gemzar, Carboplatin
IFCT, IFCT
Advanced non squamous non small cell lung cancer Cancer du poumon non à petites cellules non-épidermoïde de stade avancé, Lung cancer Cancer du poumon, Diseases [C] - Cancer [C04]
 
 
MYSTIC, NCT02453282 / 2015-001279-39: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Checkmark From MYSTIC trial in 1L mNSCLC
Apr 2020 - Apr 2020: From MYSTIC trial in 1L mNSCLC
Checkmark Results for metastatic NSCLC [MYSTIC]
Dec 2018 - Dec 2018: Results for metastatic NSCLC [MYSTIC]
Checkmark OS data from MYSTIC trial in 1L NSCLC
More
Active, not recruiting
3
1118
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
10/18
12/24
KEYNOTE-189 Japan Extension study, NCT03950674 / 2015-003694-15: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Checkmark Presentation of data from KEYNOTE-189 trial for 1L non squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from KEYNOTE-189 trial for 1L non squamous NSCLC at ESMO 2022
Checkmark Results from KEYNOTE-189 trial for 1L nonsquamous non-small cell lung cancer at ESMO
Sep 2022 - Sep 2022: Results from KEYNOTE-189 trial for 1L nonsquamous non-small cell lung cancer at ESMO
Checkmark From KEYNOTE-189 in 2L NSCLC
More
Completed
3
40
Japan
Pembrolizumab 200 mg, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg, Saline solution
Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
05/19
06/23
2018-004720-11: Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC

Ongoing
3
792
Europe, RoW
KEYTRUDA® (pembrolizumab, MK-3475), Pembrolizumab, Olaparib, ALIMTA, Pemetrexed, MK-3475, MK-7339, Solution for infusion, Film-coated tablet, Powder for concentrate for solution for infusion, KEYTRUDA® (pembrolizumab, MK-3475), ALIMTA
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Stage IV lung cancer condition, Stage IV lung cancer condition, Diseases [C] - Cancer [C04]
 
 
CheckMate 9LA, NCT03215706 / 2017-001195-35: A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Checkmark Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Opdivo for NSCLC at ASCO 2022
More
Active, not recruiting
3
719
Europe, Canada, Japan, US, RoW
Ipilimumab, Yervoy, BMS734016, Nivolumab, Opdivo, BMS936558, Carboplatin, Paclitaxel, Taxol, Pemetrexed, Alimta, Cisplatin, Platinol
Bristol-Myers Squibb
Non-Small Cell Lung Cancer
08/19
01/26
NEJ009, R000007519: Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation

Completed
3
340
Japan
gefitinib - Generic mfg., carboplatin - Generic mfg., pemetrexed - Generic mfg.
North-East Japan Study Group, MHLW
Non-small cell lung cancer
 
 
ATALANTE 1, NCT02654587 / 2015-003183-36: OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Terminated
3
219
Europe, US, RoW
OSE2101, TEDOPI, EP-2101, EP2101, IDM-2101, Docetaxel, Taxotere, Pemetrexed, Alimta
OSE Immunotherapeutics, OSE Immunotherapeutics, OSE Pharma
Non Small Cell Lung Cancer
01/21
01/21
2019-002743-26: immunotherapy alone versus immunotherapy-chemotherapy in first line treatment of lung cancer: which treatment works best?

Not yet recruiting
3
84
Europe
Powder for concentrate for solution for infusion, Powder and solution for solution for injection, Powder and solvent for concentrate for solution for infusion, Keytruda, Alimta, carboplatin, paclitaxel
Paulien van Deutekom Foundation, Paulien van Deutekom Foundation
non small cell lung cancer (NSCLC), lung cancer, Diseases [C] - Cancer [C04]
 
 
CheckMate 743, NCT02899299 / 2016-001859-43: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Checkmark Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Sep 2022 - Sep 2022: Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Checkmark Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
Checkmark Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
More
Completed
3
605
Europe, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Mesothelioma
03/20
04/23
R000007955: Randomized Phase III Study of Pemetrexed + Cisplatin and Vinorelbine + Cisplatin for Completely Resected Non-squamous Non-Small Cell Lung Cancer

Completed
3
Japan
pemetrexed - Generic mfg., cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg.
Shizuoka Cancer Center, AMED
Completely resected non-squamous non-small cell lung cancer patients (pathologic stage II-IIIA)
 
 
2019-002463-10: A study of BLU-667 in patients with lung cancer

Not yet recruiting
3
250
Europe
Pralsetinib, Carboplatin, Cisplatin, Keytruda, Gemcitabine, Pemetrexed, BLU-667, N/A, Capsule, Concentrate for solution for infusion, Powder for solution for infusion, Lyophilisate for solution for infusion, Carboplatin, Cisplatin, Keytruda, Gemcitabine, Alimta
Blueprint Medicines Corporation, F. Hoffmann-La Roche Ltd, F. Hoffmann La-Roche Ltd, BLUEPRINT MEDICINES CORPORATION, Blueprint Medicines, F.Hoffmann-La Roche Ltd., F. Hoffmann La-Roche Ltd, F. Hoffmann-La Roche Ltd.
RET fusion-positive, Metastatic Non-Small Cell Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NCT03992885: Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Recruiting
3
70
RoW
Icotinib, Pemetrexed, platinum
Tianjin Medical University Cancer Institute and Hospital
Non-squamous Non-small Cell Lung Cancer
07/20
08/25
2020-002626-86: A trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab monotherapy in first line treatment of non small-cell lung cancer (NSCLC) patients Etude comparant l’association chimiothérapie à base de sels de platine et pembrolizumab au pembrolizumab en monothérapie, en première ligne de traitement de cancers broncho-pulmonaires non à petites cellules (CBPNC)

Not yet recruiting
3
292
Europe
Pemrolizumab, carboplatine, cisplatine, paclitaxel, Pemetrexed, Powder and solvent for solution for injection, Solution for infusion, Solution for solution for injection, Solution for injection, KEYTRUDA, carboplatine, Cisplatine, paclitaxel, Pemetrexed
CHRU de Brest, CHRU de Brest
First line, stage IV non small-cell lung cancer (NSCLC) with PD L1 expression on ≥50 % of tumor cells Cancer bronchique non à petites cellules, Neoplasms benign, malignant and unspecified Oncologie médicale, Diseases [C] - Cancer [C04]
 
 
NEPTUNE, NCT02542293 / 2015-002197-21: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC)

Checkmark From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Aug 2019 - Aug 2019: From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Active, not recruiting
3
953
Europe, Japan, US, RoW
Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
09/20
12/24
RATIONALE-304, NCT03663205: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC

Checkmark From trial for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: From trial for NSCLC at ESMO 2020
Checkmark From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
Sep 2020 - Sep 2020: From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
Checkmark From trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC
More
Completed
3
334
RoW
Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed, Cisplatin or Carboplatin,Pemetrexed
BeiGene
Non-Small Cell Lung Cancer
10/20
04/23
EPIC, NCT03402048: The Trial The Elderly Patient Individualized Chemotherapy Trial

Recruiting
3
567
Europe
Carboplatin, Gemcitabine, Gemzar, Pemetrexed, Alimta, Docetaxel, Taxotere, Vinorelbine, Navelbine
University of Turin, Italy
Stage IV, NSCLC, Lung Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms
12/20
05/21
NCT02001168: Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Active, not recruiting
3
392
RoW
Pemetrexed, Alimta, Docetaxel, Taxotere, rh-Endostatin, Endostar, Cis-platinum, Platinol
Xinjiang Medical University
Non-small Cell Lung Cancer
12/20
10/22
POSEIDON, NCT03164616 / 2017-000920-81: Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer ().

Checkmark Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Checkmark Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Aug 2022 - Aug 2022: Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Checkmark Full data presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2021
More
Active, not recruiting
3
1186
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
AstraZeneca
Non Small Cell Lung Cancer NSCLC
03/21
12/26
2021-000615-23: Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with metastatic cancer in response after 6 months of standard IO

Not yet recruiting
3
646
Europe
pembrolizumab, durvalumab, atezolizumab, avelumab, bevacizumab, pemetrexed, cabozantinib, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Film-coated tablet, OPDIVO, KEYTRUDA, IMFINZI, Tecentriq, Bavencio
UNICANCER, PHRC-K 2020, Fondation BMS
Oncologic metastatic tumour (lung cancer (K), renal cell K (except IMDC favorable-risk treated TKI / immunotherapy [IO] combination), head and neck K, bladder K, triple negative breast K, Merkel K and melanoma, or hepatocellular carcinoma) in PR or CR (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI)., -, Diseases [C] - Cancer [C04]
 
 
NCT05055908: Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Recruiting
3
12000
RoW
Pemetrexed plus Pembrolizumab, Bevacizumab, Pembrolizumab, Pemetrexed
Hunan Province Tumor Hospital
Lung Cancer
07/25
09/27
2019-003969-18: A study to evaluate Chemotherapy Plus Osimertinib against Chemotherapy Plus Placebo in patients with non-small cell lung cancer (NSCLC)

Not yet recruiting
3
204
Europe
Osimertinib 80 mg, Osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD9291, Film-coated tablet, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Non-Small Cell Lung Cancer, EGFRm locally adv or metastatic Non-Small Cell Lung Cancer., Diseases [C] - Cancer [C04]
 
 
CANOPY-1, NCT03631199 / 2018-001547-32: Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Hourglass Oct 2021 - Dec 2021 : From CANOPY-1 trial in combination with Keytruda for 1L NSCLC
Checkmark PFS data from CANOPY-1 trial in combination with pembrolizumab for 1L NSCLC
Dec 2021 - Dec 2021: PFS data from CANOPY-1 trial in combination with pembrolizumab for 1L NSCLC
Checkmark P3 CANOPY-1 trial in combination with canakinumab
Dec 2018 - Dec 2018: P3 CANOPY-1 trial in combination with canakinumab
Active, not recruiting
3
673
Europe, Canada, Japan, US, RoW
canakinumab, ACZ885, canakinumab matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
08/21
06/27
CheckMate 816, NCT02998528 / 2016-003536-21: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Hourglass Oct 2023 - Oct 2023 : Additional results (Abstract #1261O) from CheckMate -816 trial of neoadjuvant Opdivo in combination with Yervoy in resectable NSCLC at ESMO 2023
Checkmark Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Checkmark EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
Apr 2022 - Apr 2022: EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
More
Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non Small Cell Lung Cancer
09/21
11/28
NVALT22, NCT02743923 / 2015-003121-34: Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Active, not recruiting
3
203
Europe
carboplatin, paclitaxel, Bevacizumab, Pemetrexed, cisplatin
The Netherlands Cancer Institute, Dutch Society of Physicians for Pulmonology and Tuberculosis
Carcinoma, Non-Small Cell Lung
09/21
04/24
2020-003562-39: Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Non-Small Cell Lung Cancer

Not yet recruiting
3
600
Europe
Zimberelimab, Domvanalimab, Carboplatin, Paclitaxel, Pemetrexed, AB122, AB154, Carboplatin, Paclitaxel, Pemetrexed, Concentrate for solution for infusion, Powder for concentrate for solution for infusion
Arcus Biosciences, Inc., Arcus Biosciences, Inc.
First Line Non-Small Cell Lung Cancer, First Line Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
2021-002193-63: A Phase 3 Study of Balstilimab Compared to Chemotherapy Chosen by the Investigator in Cervical Cancer.

Not yet recruiting
3
486
Europe
Balstilimab, pemetrexed, Gemcitabine, irinotecan, Topotecan, Vinorelbine, AGEN2034, Solution for injection, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi, Gemcitabine, Irinotecan, Topotecan, Vinorelbine
Agenus, Inc., Agenus, Inc.
recurrent, persistent, or metastatic cervical cancer that have progressed after receiving platinum-based chemotherapy, Cancer that develops in a woman's cervix, Diseases [C] - Cancer [C04]
 
 
NCT02974426: To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Terminated
3
132
RoW
PORT-first, PORT-last, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Shanghai Chest Hospital, Shanghai Pulmonary Hospital, Shanghai, China, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital, RenJi Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
02/24
02/24
ACROSS1, NCT04500704: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Not yet recruiting
3
166
RoW
Almonertinib, Ameile, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
12/21
10/23
JAVELIN Lung 100, NCT02576574 / 2015-001537-24: Avelumab in First-line NSCLC

Checkmark Data from JAVELIN Lung 100 trial for 1L NSCLC
Feb 2022 - Feb 2022: Data from JAVELIN Lung 100 trial for 1L NSCLC
Checkmark Avelumab program rollover study in solid tumor
Jan 2019 - Jan 2019: Avelumab program rollover study in solid tumor
Checkmark Registration study for 1L NSCLC
More
Completed
3
1214
Europe, Canada, Japan, US, RoW
Avelumab, Anti-PD-L1, MSB0010718C, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
First Line Non-Small Cell Lung Cancer
12/21
01/24
CTONG2003, NCT04768075: Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Not yet recruiting
3
200
NA
Camrelizumab, SHR-1210, Placebo, Simulator of Camrelizumab, Cisplatin, cisplatinum, Carboplatin, Carboplat, Pemetrexed, Pemetrexed disodium, Paclitaxel, Paclitaxel injection, Albumin paclitaxel, Nab-paclitaxel
Guangdong Association of Clinical Trials
Non-Small-Cell Lung Cancer
04/22
04/24
NACA, NCT02607592: A Prospective Multi-center Phase III Randomized Controlled Trial

Recruiting
3
293
RoW
cisplatin and pemetrexed, nedaplatin+pemetrexed
Sun Yat-sen University
Carcinoma，Non-Small-Cell Lung
06/22
12/22
NCT01951469: Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Recruiting
3
160
RoW
Gefitinib and Pemetrexed/platinum, Gefitinib mono-therapy
Sun Yat-sen University, Wu Jieping Medical Foundation
Non-small Cell Lung Cancer, Brain Metastases, EGFR Mutation
06/22
12/22
EVIDENCE, NCT02448797: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Active, not recruiting
3
320
RoW
Icotinib, Conmana, Chemotherapy, Navelbine, ALIMTA
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
06/22
12/23
2021-006374-24: A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico

Not yet recruiting
3
324
Europe
Savolitinib, osimertinib 80 mg, osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD6094, HMPL-504, AZD9291, Tablet, Film-coated tablet, Concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo, Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
2021-005879-40: Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Estudio en fase III de patritumab deruxtecán frente a quimioterapia basada en platino en el CPNM metastásico o localmente avanzado con EGFRm tras el fracaso del tratamiento con ITC del EGFR

Not yet recruiting
3
560
Europe
Patritumab Deruxtecan, Pemetrexed, Cisplatin, Carboplatin, U3-1402, NA, Powder for solution for infusion, Concentrate for solution for infusion, Solution for infusion, Vitamin B12 1000 µg, Folic Acid, Cisplatin, carboplatin, pemetrexed
Daiichi Sankyo, Inc., DAIICHI SANKYO INC., DAIICHI SANKYO. INC., Daiichi Sankyo, Inc.
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM) metastásico o localmente avanzado con mutación del receptor del factor de crecimiento epidérmico (EGFRm), Non-small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM), Diseases [C] - Cancer [C04]
 
 
ChiCTR2000037269: PD-1 inhibitor plus chemotherapy and VEGFR inhibitor or placebo in advanced non-squamous NSCLC patients: a randomized, controlled, multicenter, phase III study

Recruiting
3
534
 
camrelizumab+famitinib+pemetrexed+carboplatin ;camrelizum+pemetrexed+carboplatin
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Shanghai Shenkang Hospital Development Center
lung cancer
 
 
TOP, NCT04695925: Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations

Not yet recruiting
3
291
RoW
Osimertinib 80 MG [Tagrisso], Pemetrexed 500 MG Injection, Carboplatin
Li Zhang, MD
Non-small Cell Carcinoma, EGFR Gene Mutation
09/22
12/23
ACROSS2, NCT04500717: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Not yet recruiting
3
460
RoW
Almonertinib, Aleime, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
10/22
10/23
PEARL, NCT03003962 / 2018-001375-21: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer

Checkmark Data from PEARL trial for Stage IV (metastatic) NSCLC
Dec 2022 - Dec 2022: Data from PEARL trial for Stage IV (metastatic) NSCLC
Checkmark From PEARL trial for 1L NSCLC
Oct 2021 - Oct 2021: From PEARL trial for 1L NSCLC
Active, not recruiting
3
669
Europe, US, RoW
Durvalumab (MEDI4736), Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
10/22
06/26
AEGEAN, NCT03800134 / 2018-002997-29: A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Event free survival data from AEGEAN trial for stage I and III resected NSCLC
Jan 2023 - Dec 2023: From AEGEAN trial for stage II and III resected NSCLC
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan for advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU for advanced stage 3 NSCLC (based on AEGEAN trial)
Jan 2023 - Dec 2023: Regulatory submission for locally advanced stage 3 NSCLC (based on AEGEAN trial)
More
Active, not recruiting
3
826
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
AstraZeneca
Non-Small Cell Lung Cancer
11/22
09/28
NCT03381066: A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Recruiting
3
225
RoW
gefitinib, pemetrexed,cisplatin, Intercalating arm, Vinorelbine, cisplatin, chemotherapy alone arm
Yonsei University
Completely Resected NSCLC With Common EGFR Mutations
12/22
12/22
NCT04619433: A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Recruiting
3
560
RoW
Camrelizumab;Pemetrexed and Carboplatin; Famitinib;, SHR1210, Camrelizumab;Pemetrexed and Carboplatin;Placebo
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous Non-small-cell Lung Cancer
12/22
10/23
KEYNOTE-789, NCT03515837 / 2017-004188-11: Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/)

Completed
3
492
Europe, Canada, Japan, US, RoW
pembrolizumab, MK-3475, pemetrexed, carboplatin, cisplatin, saline solution, Normal saline solution
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
01/23
10/23
IMpower151, NCT04194203: A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting
3
305
RoW
Atezolizumab, Tecentriq, Placebo, Bevacizumab, Avastin, Paclitaxel, Pemetrexed, Carboplatin
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
02/23
06/24
ORIENT-11, NCT03607539: Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Checkmark Accepted for review for the treatment of Nonsquamous NSCLC
May 2021 - May 2021: Accepted for review for the treatment of Nonsquamous NSCLC
Checkmark Data from orient-11 trial with or without combination of pemetrexed plus platinum chemotherapy for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from orient-11 trial with or without combination of pemetrexed plus platinum chemotherapy for NSCLC at ESMO 2020
Checkmark From ORIENT-11 trial for advanced or metastatic NSCLC at ESMO 2020
More
Completed
3
397
RoW
Sintilimab, IBI308, Pemetrexed, Platinum, Placebos
Innovent Biologics (Suzhou) Co. Ltd.
Lung Neoplasms
02/23
02/23
ATTLAS, NCT03991403: Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Active, not recruiting
3
228
RoW
Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab, Carboplatin, Paclitaxel, Carboplatin or cisplatin
Samsung Medical Center
Non-small Cell Lung Cancer
03/23
03/24
FLAURA2, NCT04035486 / 2019-000650-61: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer

Hourglass Jan 2024 - Mar 2024 : Q1'24 - PDUFA date for FDA approval in adults with locally advanced/metastatic EGFRm NSCLC (based on FLAURA2 trial)
Jan 2022 - Dec 2023: Data from FLAURA2 trial in combination with carboplatin or pemetrexed/cisplatin for 1L EGFRm NSCLC
Active, not recruiting
3
587
Europe, Canada, Japan, US, RoW
Osimertinib, AZD9291, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
AstraZeneca
Non-Small Cell Lung Cancer
04/23
06/26
KEYNOTE-A86, NCT04956692 / 2020-002729-27: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Active, not recruiting
3
531
Europe, Japan, US, RoW
Pembrolizumab SC, Pembrolizumab IV, MK-3475, KEYTRUDA®, SCH 900475, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-Paclitaxel, Abraxane, Nanoparticle albumin-bound paclitaxel, Carboplatin, Paraplatin, Paraplatin NovaPlus, Cisplatin, Platinol-AQ, Pemetrexed, LY231514, Alimta, Pemetrexed Disodium
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Non-Small Cell Lung Cancer
04/23
10/26
ORIENT-31, NCT03802240: Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Checkmark Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Checkmark Interim analysis results of ORIENT-31 study of sintilimab plus Byvasda and chemo in EGFR-mutated nonsquamous NSCLC at ESMO Virtual Plenary 2021
Nov 2021 - Nov 2021: Interim analysis results of ORIENT-31 study of sintilimab plus Byvasda and chemo in EGFR-mutated nonsquamous NSCLC at ESMO Virtual Plenary 2021
Checkmark Data from first interim analysis in combination with Byvasda and chemo in EGFR mutated nonsquamous NSCLC
More
Completed
3
492
RoW
Sintilimab, IBI308, IBI305, Pemetrexed, Cisplatin, Placebo1, Placebo2
Innovent Biologics (Suzhou) Co. Ltd.
Non-Squamous Non-Small Cell Lung Cancer
07/21
06/23
LIBRETTO-431, NCT04194944 / 2019-001979-36: A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Active, not recruiting
3
261
Europe, Canada, Japan, RoW
Selpercatinib, LY3527723, LOXO-292, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer
05/23
06/26
ChiCTR2000032288: PD-1 antibody plus chemotherapy versus bevacizumab plus chemotherapy as first-line treatment for patients with PD-L1 negative and EGFR/ALK wild-type advanced or metastatic non-squamous non-small cell lung cancer : an open-label, randomised, multicentre phase 3 trial

Not yet recruiting
3
510
 
Camrelizumab + pemetrexed + carboplatin / cisplatin ;Bevacizumab + pemetrexed + carboplatin / cisplatin
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Clinical Research foundation of Shanghai Pulmonary Hospital
Lung Cancer
 
 
NCT06396065: Phase III Study of AK112 for NSCLC Patients

Recruiting
3
420
Europe, Canada, US
AK112 Injection, Pemetrexed, Carboplatin, Placebo Injection
Summit Therapeutics, Akeso
Non-Squamous Non-small Cell Lung Cancer
12/25
12/25
NCT06212752: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Active, not recruiting
3
378
Japan
Pembrolizumab coformulated with hyaluronidase, MK-3475A, Pemetrexed, Alimta, Cisplatin, Platinol-AQ, Carboplatin, Paclitaxel, Taxol, Nab-paclitaxel, Albumin-bound paclitaxel, Pembrolizumab, MK-3475, KEYTRUDA, Filgrastim, Pegylated filgrastim
Merck Sharp & Dohme LLC
Metastatic Non-small Cell Lung Cancer
09/24
05/28
AK105-301, NCT03866980: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Terminated
3
164
RoW
AK105, carboplatin, pemetrexed, placebo, Anlotinib
Akeso, Akeso Tiancheng, Inc
Lung Cancer Non-small Cell Stage IV
06/23
12/23
MARIPOSA-2, NCT04988295: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Active, not recruiting
3
776
Europe, Canada, Japan, US, RoW
Lazertinib, JNJ-73841937, YH-25448, Amivantamab, JNJ-61186372, Pemetrexed, Carboplatin
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
07/23
12/25
2022-002006-24: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Estudio para comparar furmonertinib con quimioterapia basada en platino para pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico

Not yet recruiting
3
375
Europe
Furmonertinib, AST2818, Tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion, Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Carboplatin Hikma 10 mg/mL concentrate for solution for infusion, Carboplatin Bendalis 10 mg/ml Concentrate for solution for infusion, Carboplatin Fresenius Kabi 10 mg/ml, concentrate for solution for infusion, Cisplatin Hikma 1mg/ml concentrate for solution for infusion, Cisplatin Accord 1 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml concentrate for solution for infusion
ArriVent BioPharma, Inc., ArriVent BioPharma, Inc., Shanghai Allist Pharmaceuticals Co., Ltd.
Treatment of Patients with Previously Untreated, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide sin tratamiento previo, localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del receptor del factor de crecimiento epidérmico (RFCE), Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
NCT03924050: Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Recruiting
3
440
RoW
TORIPALIMAB INJECTION(JS001 )
Shanghai Junshi Bioscience Co., Ltd.
Non-small Cell Lung Cancer
07/23
08/24
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
568
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
ACROSS 1, ChiCTR2000032354: Almonertinib Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Patients With EGFR Mutation Positive With Concomitant Non-EGFR Driver Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Recruiting
3
166
 
Almonertinib 110mg PO once daily ;110mg PO once daily and 500 milligrams per square meter (mg/m2) Pemetrexed and AUC=5 Carboplatin taken intravenously (IV) once every 3 weeks concurrently with Almonertinib taken orally QD.
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd
NSCLC
 
 
ACROSS 2, ChiCTR2000032319: Almonertinib Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Patients With EGFR Mutation Positive With Concomitant Tumor Suppressor Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Recruiting
3
460
 
Almonertinib, 110mg, P.O., once daily and 500 milligrams per square meter (mg/m2) Pemetrexed and AUC=5 Carboplatin taken intravenously (IV) once every 3 weeks concurrently with Almonertinib taken orally QD. ;Almonertinib, 110mg, P.O., once daily
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd.
NSCLC
 
 
CRYOMUNE, NCT04339218: Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

Recruiting
3
214
Europe
Cryoablation, Pembrolizumab, Pemetrexed, Carboplatin
Institut Bergonié
Lung Adenocarcinoma, Cryotherapy Effect
08/23
08/25
LEAP-006, NCT03829319 / 2018-003824-35: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/)

Checkmark Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Sep 2020 - Sep 2020: Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Checkmark Data from LEAP-006 trial in combination with pembrolizumab & platinum doublet chemo in mNSCLC at ESMO 2020
Jul 2020 - Jul 2020: Data from LEAP-006 trial in combination with pembrolizumab & platinum doublet chemo in mNSCLC at ESMO 2020
Checkmark Data from LEAP-006 trial in combination with lenvatinib & platinum doublet chemo in mNSCLC at ESMO 2020
More
Active, not recruiting
3
761
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
LEAP-006 China Extension, NCT04716933: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Active, not recruiting
3
201
RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
ORIENT-99, NCT05116462: Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Recruiting
3
500
RoW
Pemetrexed, Carboplatin, Paclitaxel, Sintilimab, Cisplatin, Nab paclitaxel, Placebo
Innovent Biologics (Suzhou) Co. Ltd.
Non-Small Cell Lung Cancer
09/26
10/28
TREBLE, NCT05493501: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated
3
8
US
Aumolertinib monotherapy, EQ143, HS-10296, Osimertinib monotherapy, Tagrisso, Pemetrexed, Alimta, Cisplatin, Carboplatin, Paclitaxel, Taxol, Nab paclitaxel, Abraxane, Albumin-bound paclitaxel, Gemcitabine, Gemzar
EQRx International, Inc.
NSCLC
08/23
08/23
PACIFIC2, NCT03519971 / 2017-004397-34: Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Jul 2023 - Dec 2023: Data from PACIFIC-2 trial for advanced NSCLC
Jul 2023 - Dec 2023: Acceptance of regulatory submission for CRT+ NSCLC (based on PACIFIC-2 trial)
Hourglass Jan 2021 - Dec 2021 : Regulatory submission for advanced stage 3 NSCLC (based on PACIFIC-2 trial)
Active, not recruiting
3
328
Europe, Japan, RoW
Durvalumab, MEDI4736, Placebo, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel, Pemetrexed/ Cisplatin, Pemetrexed/ Carboplatin, Radiation
AstraZeneca
Non-Small Cell Lung Cancer
09/23
03/25
PAPILLON, NCT04538664 / 2020-000633-40: A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Active, not recruiting
3
308
Europe, Canada, Japan, US, RoW
Amivantamab, JNJ-61186372, Pemetrexed, Carboplatin
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
05/23
01/26
NCT03952403: A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
643
RoW
HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin, Pemetrexed
Shanghai Henlius Biotech
Carcinoma, Non-Small-Cell Lung
10/23
03/24
DOMAJOR, NCT03912389 / 2018-004791-36: Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

Recruiting
3
292
Europe, RoW
BCD-100, Pemetrexed, Cisplatin (or carboplatin), Placebo
Biocad
Non-Squamous Non-Small Cell Neoplasm of Lung
12/23
12/23
NCT05346952: A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Recruiting
3
390
RoW
TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Non-squamous Non-small Cell Lung Cancer
12/23
12/23
CheckMate 77T, NCT04025879 / 2019-000262-38: A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Data readout CheckMate-77T trial for peri adjuvant NSCLC
Hourglass Nov 2023 - Mar 2024 : H2 FY’23 - Submission in Japan for neoadjuvant/adjuvant NSCLC based on CheckMate-77T trial
Active, not recruiting
3
482
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS936558, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel
Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung
07/23
09/24
IPAN study, ChiCTR2100043426: A multicenter, randomized, open-label, phase III clinical trial of Icotinib plus pemetrexed-cisplatin versus pemetrexed-cisplatin as postoperative adjuvant treatment in stage III (N1-N2) non-small cell lung cancer (NSCLC) with EGFR-sensitive mutation

Recruiting
3
155
 
Icotinib Hydrochloride Tablets ;Pemetrexed Disodium for Injection ;Carboplatin Injection ;Cisplatin Injection ;Icotinib Hydrochloride Tablets
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-financing
Non-small cell lung cancer
 
 
Beamion LUNG-2, NCT06151574: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Recruiting
3
270
Europe, Japan, US, RoW
zongertinib, BI 1810631, pembrolizumab, Keytruda®, cisplatin, carboplatin, pemetrexed
Boehringer Ingelheim
Lung Cancer, Non-squamous, Non-small Cell
03/27
05/28
KEYNOTE-671, NCT03425643 / 2017-001832-21: Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/)

Calendar Jan 2024 - Dec 2024: From KEYNOTE-0671 trial for resectable stage IIb or IIIa NSCLC
Hourglass Sep 2019 - Oct 2019 : Preliminary data from trial for advanced solid tumors and genomic instability at ESMO 2019
Active, not recruiting
3
797
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Placebo, Cisplatin, PLATINOL®, Gemcitabine, GEMZAR®, Pemetrexed, Alimta®
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/23
06/26
BEAT-meso, NCT03762018 / 2018-002180-25: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Active, not recruiting
3
401
Europe
Carboplatin, Carboplatin Accord, Pemetrexed, Alimta, Bevacizumab, Avastin, Atezolizumab, Tecentriq, RO5541267
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Pleural Mesothelioma Malignant Advanced
06/24
06/24
NCT04585490: Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Recruiting
3
48
US
Durvalumab, Imfinzi, MEDI-4736, MEDI4736, Carboplatin, Carboplat, Carbosol, Carboplatino, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum, Pemetrexed, Alimta, MTA, LY231514, L-glutamic acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), Paclitaxel, Praxel, Cisplatin, platinum diamminodichloride, Abiplatin, Cismaplat, cis-platinum, Platinex, platinum, diaminedichloro-, cis- (8CI), AVENIO ctDNA Surveillance Kit, Tremelimumab, Imjudo, Tremelimumab-actl, Ticilimumab, CP-675, CP-675,206
Maximilian Diehn, AstraZeneca
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
04/26
04/28
NIRVANA-LUNG, NCT03774732: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

Recruiting
3
327
Europe, RoW
Radiotherapy, 3D-CRT or SABR, Pembrolizumab, Chemotherapy, Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed
UNICANCER, National Cancer Institute, France
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
09/26
09/26
NCT06281964: Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Not yet recruiting
3
327
NA
PLB1004, Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab
Avistone Biotechnology Co., Ltd.
Non-Small-Cell Lung Cancer
01/26
12/26
Neotorch, NCT04158440: Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Checkmark Results from Neotorch trial in combination with platinum-containing doublet chemotherapy for resectable stage II-III NSCLC
Jan 2023 - Jan 2023: Results from Neotorch trial in combination with platinum-containing doublet chemotherapy for resectable stage II-III NSCLC
Active, not recruiting
3
501
RoW
4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab, Cisplatin;, Carboplatin;, Pemetrexed;, Paclitaxel;, Docetaxel, 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
Shanghai Junshi Bioscience Co., Ltd.
Stage II-III Non-small Cell Lung Cancer
03/24
10/24
MK-2870-019, NCT06312137: A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR)

Recruiting
3
780
Europe, US, RoW
Sacituzumab tirumotecan, MK-2870, Pembrolizumab, MK-3475, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel
Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
02/34
10/34
NCT06380348: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not yet recruiting
3
398
NA
JMT101 Injection, Osimertinib tablet, Cisplatin injection, Pemetrexed injection
Shanghai JMT-Bio Inc.
Local Advanced or Metastatic NSCLC
03/27
03/28
EMPOWER-lung 1, NCT03088540 / 2016-004407-31: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Checkmark OS and PFS data for advanced or metastatic 1L NSCLC
Jul 2021 - Jul 2021: OS and PFS data for advanced or metastatic 1L NSCLC
Checkmark Approval in US for 1L NSCLC
Feb 2021 - Feb 2021: Approval in US for 1L NSCLC
Checkmark Data from study for advanced or metastatic PD L1+ve 1L NSCLC
More
Active, not recruiting
3
712
Europe, RoW
Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin, cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, Sanofi
Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
06/25
06/25
ALINA, NCT03456076 / 2017-004331-37: A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Active, not recruiting
3
257
Europe, Japan, US, RoW
Alectnib, RO5424802, Cisplatin, Vinorelbine, Navelbine, Gemcitabine, Gitrabin, Pemetrexed, Alimta®, Carboplatin
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
06/23
11/26
BL-B01D1-301, NCT06382116: A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
3
428
RoW
BL-B01D1, Pemetrexed+Cisplatin or Carboplatin
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
05/26
05/26
DREAM3R, NCT04181411: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Not yet recruiting
3
480
NA
Durvalumab, Imfinzi, MEDI4736, Cisplatin, Cisplatin injection, Pemetrexed, Alimta, Carboplatin, Carboplatin injection
University of Sydney, Australasian Lung Cancer Trials Group, PrECOG, LLC., AstraZeneca
Mesothelioma Malignant Advanced
06/24
06/24
 

Download Options